

# Proof of mechanism study of an oral Hedgehog Inhibitor (GDC-0449) in patients with resectable pancreatic ductal adenocarcinoma in the pre-operative window period

|  |  |  |
|--|--|--|
| <b>Submission date</b><br>14/03/2011   | <b>Recruitment status</b><br>Stopped   | <input type="checkbox"/> Prospectively registered    |
|  |  | <input type="checkbox"/> Protocol                    |
| <b>Registration date</b><br>14/03/2011 | <b>Overall study status</b><br>Stopped | <input type="checkbox"/> Statistical analysis plan   |
|  |  | <input type="checkbox"/> Results                     |
| <b>Last Edited</b><br>22/06/2015       | <b>Condition category</b><br>Cancer    | <input type="checkbox"/> Individual participant data |
|  |  | <input type="checkbox"/> Record updated in last year |

## Plain English summary of protocol

<http://cancerhelp.cancerresearchuk.org/trials/a-study-gdc-0449-before-surgery-for-pancreatic-cancer-hippos>

## Contact information

### Type(s)

Scientific

### Contact name

Ms Lisa Bax

### Contact details

Cambridge Cancer Trials Centre  
Box 279  
Hills Road  
Cambridge  
United Kingdom  
CB2 0QQ

-  
[lisa.bax@addenbrookes.nhs.uk](mailto:lisa.bax@addenbrookes.nhs.uk)

## Additional identifiers

Clinical Trials Information System (CTIS)

2010-018776-24

[ClinicalTrials.gov \(NCT\)](https://clinicaltrials.gov/ct2/show/study/NCT01877624)

NCT01096732

**Protocol serial number**

9531

## Study information

**Scientific Title**

Proof of mechanism study of an oral Hedgehog Inhibitor (GDC-0449) in patients with resectable pancreatic ductal adenocarcinoma in the pre-operative window period: a non randomised study

**Acronym**

HIPPoS

**Study objectives**

This clinical trial is looking at the effect of a new drug called GDC0449 in patients with cancer of the pancreas.

Laboratory studies have shown that this drug blocks a process in pancreatic cells thought to be involved in cancer development and spread. This process is called the Hedgehog signalling pathway. As yet, it is unclear whether blocking hedgehog signalling will directly affect the tumour cells themselves or the surrounding normal tissue.

Understanding this distinction will help improve treatment strategies for pancreatic cancer. Patients will be offered to participate in this research study if they have localised pancreatic cancer that can be removed by surgery. In the period between diagnosis and surgery we do not normally treat patients, however in this trial we will ask patients to take GDC0449 during the approximately two weeks until the day of surgery. All patients that enter this study will have undergone a diagnostic biopsy of the pancreatic tumour and we will collect a second sample of the tumour at surgery. The main question of this study is whether we can detect a change in hedgehog signalling in the tumour tissue.

Furthermore we will look very carefully whether this treatment is safe for patients. All problems before and after surgery will be carefully documented and we have defined strict rules to stop the study if we observe serious problems.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Cambridgeshire 1 REC, 21/10/2010, ref: 10/H0304/76

**Study design**

Non-randomised, Interventional; Design type: Treatment

**Primary study design**

Interventional

**Study type(s)**

Treatment

## Health condition(s) or problem(s) studied

Topic: National Cancer Research Network; Subtopic: Upper Gastro-Intestinal Cancer; Disease: Pancreas

## Interventions

Adverse Event Monitoring: Blood sampling, Maximum of 212ml; Concomitant Medications, electrocardiogram (ECG), endoscopic ultrasound (EUS) and contrast / elastography; Physical Exam, Urinalysis, Study Entry : Registration only

Updated 22/06/2015: The study was stopped early due to poor recruitment.

## Intervention Type

Other

## Phase

Phase II

## Primary outcome(s)

Effect on stromal cell and tumour; Timepoint(s): To study the effect of GDC0449 treatment on the stromal cell and tumour cell hedgehog signalling

## Key secondary outcome(s)

Safety & Tolerability; Timepoint(s): To study the safety and tolerability of preoperative GDC0449 treatment in patients

## Completion date

31/05/2012

## Reason abandoned (if study stopped)

Participant recruitment issue

# Eligibility

## Key inclusion criteria

1. Documented tissue diagnosis of pancreatic ductal adenocarcinoma with a sufficient amount of tissue for Laser Capture Micro-dissection (LCM) of the stromal and tumour compartments
2. Confirmed eligibility for Whipple's or distal pancreatectomy procedure by Multi-Disciplinary Team (MDT) and surgeon review.
3. Adequate organ function defined as:
  - 3.1. Creatinine clearance = 60ml/min (as defined by Cockcroft-Gault)
  - 3.2. Electrolytes (Na/K/Ca) within institutional normal limits
  - 3.3. Alanine aminotransferase (ALT)/aspartate aminotransferase(AST) < 5\*ULN
  - 3.4. Prothrombin time test (PTT) < 2\*ULN, prior supplementation with vitamin K is allowed
  - 3.5. Adequate blood counts: neutrophils >1,500/ $\mu$ l, Hb > 6 mmol/L, platelets >100.000/ $\mu$ l
  - 3.6. Albumin > 30mg/dL
4. Written informed consent
5. Male or female aged 18 years or over
6. WHO performance status 0-1
7. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests and other study procedures

8. Males should not donate sperm during treatment or up to 3 months after the last dose  
9. Women of childbearing potential are required to have a negative serum pregnancy test (with sensitivity of at least 25 mIU/mL) within 10-14 days and within 24 hours prior to the first dose of GDC-0449

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Sex**

All

**Key exclusion criteria**

1. Known Hepatitis B/C or HIV infection
2. Known hypersensitivity to GDC-0449
3. Active cardiac ischemic disease (this criterion only applies for participation in the imaging part of the study)
4. Women who are pregnant, plan to become pregnant or are lactating (during the study or for up to 12 months after the last dose)
5. Concurrent participation in another clinical trial using an investigational medicinal product
6. Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or study drug administration or in the judgment of the investigator would make it undesirable for the patient to enter the trial (i.e. patients is not able to swallow tablets)

**Date of first enrolment**

14/02/2011

**Date of final enrolment**

31/05/2012

**Locations****Countries of recruitment**

United Kingdom

England

**Study participating centre**

Cambridge Cancer Trials Centre  
Cambridge

United Kingdom  
CB2 0QQ

## Sponsor information

### Organisation

Cambridge University Hospitals NHS Foundation Trust (UK)

### ROR

<https://ror.org/04v54gj93>

## Funder(s)

### Funder type

Government

### Funder Name

Cambridge University Hospitals NHS Foundation Trust (UK)

### Funder Name

Roche Products Ltd (UK)

## Results and Publications

### Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not provided at time of registration

### Study outputs

| Output type                          | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|--------------------------------------|---------|--------------|------------|----------------|-----------------|
| <a href="#">HRA research summary</a> |         |              | 28/06/2023 | No             | No              |